Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Child Development Disorders, Pervasive: early-phase trial registry

1 of 5 indexed Child Development Disorders, Pervasive trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Child Development Disorders, Pervasive: 5 US clinical trials tracked, 1 recruiting.

Child Development Disorders, Pervasive is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital Medical Center, Cincinnati, running 2 of these trials.

Enrollment posture brief

Registry condition child-development-disorders-pervasive

OPEN 1 | RECR 20% | LATE 0 | EARLY 3 | RANK #3391 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Child Development Disord (th…20%
Open-enrollment share among volume-matched conditions near Child Development Disorders, Pervasive

Child Development Disorders, Pervasive lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Child Development Disorders, Pervasive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Child Development Disorders, Pervasive is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Child Development Disorders, Pervasive research.

    Children's Hospital Medical Center, Cincinnati accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Child Development Disorders, Pervasive enrolment sits around 100 participants.

    Median target enrolment is 100 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Child Development Disorders, Pervasive research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Named interventions

Most-linked intervention names on Child Development Disorders, Pervasive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Risperidone Drug
3 trials
Behavior Therapy Behavioral
1 trials
N-acetylcysteine Drug
1 trials
SQUED™ series 28.1 home-use Device
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Child Development Disorders, Pervasive trials. A trial with sites in several states counts in each.

Ohio 3 trials
North Carolina 2 trials
Michigan 2 trials
Indiana 2 trials
Kentucky 1 trials
Connecticut 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Child Development Disorders, Pervasive page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Child Development Disorders, Pervasive condition card totals 5 registered trials; most-linked intervention Risperidone; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.